← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oncoimmune, Inc.
Rockville, MD
$11,499,817
Total funding
12
Grants
Funding over time
peak $3.3M · FY2008–20$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$10,514,385 · 11
FDA$985,432 · 1
By mechanism
R44$8,420,643 · 6
R01$2,065,719 · 2
R43$700,741 · 3
R41$312,714 · 1
Investigators at Oncoimmune, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competing Renewal$1,444,734
R44 · FY2009 · NS
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$1,017,478
R44 · FY2017 · CA
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$1,014,321
R44 · FY2019 · CA
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients$1,000,000
R44 · FY2020 · CA
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$985,075
R44 · FY2020 · CA
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$982,509
R44 · FY2018 · CA
CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study$546,203
R01 · FY2013 · NS
CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study$534,084
R01 · FY2014 · NS
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)$500,000
R01 · FY2018 · FD
CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competing Renewal$493,610
R44 · FY2010 · NS
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)$485,432
R01 · FY2020 · FD
CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competing Renewal$469,280
R44 · FY2008 · NS
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$400,000
R44 · FY2020 · CA
Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)$396,664
R44 · FY2020 · CA
Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.$312,714
R41 · FY2019 · OD
A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients$212,653
R44 · FY2019 · HL
Targeting endogenous sialidases for treatment of endotoxic shock$199,956
R43 · FY2014 · AI
Targeting endogenous sialidases for treatment of endotoxic shock$195,452
R43 · FY2015 · AI
Novel Therapeutics for Sepsis$155,180
R43 · FY2011 · AI
Targeting host response to DAMP for therapy of Rheumatoid Arthritis$150,153
R43 · FY2011 · AR